Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
BioXcel Therapeutics is a clinical-stage biopharmaceutical company developing AI-powered drug candidates for neuroscience and immuno-oncology. Its lead asset BXCL501 (sublingual dexmedetomidine film) targets acute agitation in schizophrenia and bipolar disorder, with IGALMI approved by FDA in April 2022. The company operates with minimal revenue, burning approximately $100M annually while pursuing commercialization of IGALMI and advancing pipeline candidates including BXCL701 for prostate cancer.
BioXcel operates a capital-intensive drug development model, investing heavily in clinical trials and regulatory approvals before generating meaningful revenue. IGALMI represents the first commercial product, targeting the $2B+ acute agitation market with a differentiated sublingual delivery mechanism that avoids injection. Pricing power depends on demonstrating clinical superiority and securing favorable reimbursement from payers. The company's AI-driven drug identification platform aims to reduce development timelines and costs, though this remains unproven at scale. Monetization occurs through direct sales, potential licensing deals, or acquisition by larger pharmaceutical companies.
IGALMI commercial uptake metrics - quarterly prescription volumes, formulary wins, hospital adoption rates
Clinical trial readouts for pipeline candidates (BXCL701 Phase 2 prostate cancer data, BXCL502 opioid withdrawal studies)
FDA regulatory decisions, label expansions, or safety updates for approved products
Cash runway announcements, equity financings, or partnership deals that extend operational viability
Competitive developments in acute agitation space (generic alternatives, competing mechanisms)
Binary clinical trial risk - single failed Phase 3 study can eliminate years of investment and render company value near-zero
Regulatory pathway uncertainty - FDA approval timelines unpredictable, potential for Complete Response Letters requiring additional costly trials
Reimbursement pressure - payers increasingly scrutinizing specialty pharmaceutical pricing, particularly for psychiatric medications with generic alternatives
Patent cliff exposure - IGALMI composition of matter patents expire in 2030s, limiting commercial exclusivity window
Acute agitation market has established generic alternatives (IM olanzapine, IM haloperidol) at fraction of IGALMI's cost, limiting formulary adoption
Larger pharmaceutical companies (Eli Lilly, Johnson & Johnson) developing competing mechanisms with superior clinical profiles or delivery systems
BXCL701 prostate cancer program faces entrenched competition from Pfizer, AstraZeneca, and Merck with approved therapies and deeper clinical pipelines
Negative equity position (Price/Book of -0.3x) indicates liabilities exceed assets, signaling distressed financial condition
Negative Debt/Equity ratio of -1.23 mathematically reflects negative shareholder equity, not favorable leverage
Operating cash flow of -$100M annually with minimal revenue requires continuous equity dilution or asset sales to fund operations
Market cap near zero suggests high probability of reverse stock split, delisting risk, or bankruptcy absent immediate financing
low - Pharmaceutical demand for acute psychiatric conditions is relatively inelastic to GDP fluctuations. Hospital formulary decisions and treatment protocols are driven by clinical efficacy rather than economic cycles. However, payer reimbursement pressure may intensify during recessions, and venture capital availability for follow-on financings becomes constrained during economic downturns, critical for pre-profitable biotechs.
Rising interest rates negatively impact BioXcel through multiple channels: (1) Higher discount rates compress NPV of distant future cash flows, particularly punitive for clinical-stage assets 5-10 years from profitability; (2) Increased cost of capital makes equity and debt financings more dilutive; (3) Risk-off sentiment shifts investor preference away from speculative biotechs toward profitable, cash-generative businesses; (4) Competition for capital intensifies as safer fixed-income yields become attractive. The company's negative cash flow and need for ongoing financing make it highly sensitive to rate-driven valuation compression.
Moderate - While BioXcel doesn't rely on credit markets for operations, its ability to secure non-dilutive financing (venture debt, royalty agreements) deteriorates when credit spreads widen. Tighter credit conditions also pressure potential acquirers' M&A capacity and reduce likelihood of partnership deals with upfront payments. Current ratio of 1.17 indicates limited liquidity buffer, making access to capital markets critical for survival.
momentum - Attracts highly speculative traders and biotech-focused hedge funds betting on binary clinical catalysts or acquisition rumors. Not suitable for value investors (negative book value), growth investors (no sustainable revenue model yet), or dividend investors (no cash generation). Typical holders include retail momentum traders, biotech-specialized funds, and event-driven arbitrageurs positioning ahead of FDA decisions or trial readouts. Institutional ownership likely minimal given distressed financials.
high - Clinical-stage biotechs with single-digit million market caps exhibit extreme volatility, often moving 30-50% on clinical trial news, FDA announcements, or financing rumors. Illiquid float amplifies price swings. Historical beta likely exceeds 2.0x relative to broader market. Stock price has declined 72% over six months, indicating severe downward momentum and capitulation selling. Options market likely illiquid with wide bid-ask spreads.
